126 results about "Serum lipid levels" patented technology

The present invention relates to a micro-particle for extending satiety and controlling blood glucose and lipid levels, comprising a core having the protein extract from sweet potato, an active ingredient layer coated on the core, and a protection layer coated over the active ingredient layer as an external layer, wherein the protein extract from sweet potato contains trypsin inhibitor and glycoprotein. The micro-particle comprising a protein extract from sweet potato can effectively extend satiety, control blood glucose and lipid levels and increase metabolism effectively.

The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

The invention relates to blood lipid-lowering active fractions of forsythia suspensa and a preparation method and use of the same. The active fractions are ethyl acetate fractions obtained by concentrating an extract which is extracted from forsythia suspensa leaves by acetone and water. The compound of phillygenin prepared by the invention and the active fractions, namely the ethyl acetate fractions, at which the phillygenin is positioned have good antioxidant activity in vitro. In-vivo experiments show that the ethyl acetate fractions and the phillygenin can lower total cholesterols and low-density lipoprotein cholesterin in the blood serum of a mouse with hyperlipidemia and can lower blood lipid level by an oxidative approach (raising superoxide dismutase SOD and lowering malonydialdehyde MDA). In addition, the ethyl acetate fractions have a better effect of reducing the total cholesterols in the blood serum of the mouse than the phillygenin and cassia seed blood lipid-lowering tablets. The ethyl acetate fractions of the forsythia suspensa leaves can be further developed to play a role in the multi- target co-prevention and treatment of hyperlipidemia and other diseases and have a good application prospect.

The invention discloses a composition of probiotic fermented horseradish tree leaves as well as a preparation method and application of the composition. The preparation method comprises the following steps: crushing and immersing horseradish tree leaves; adding glucose, peptone, yeast extract, yeast powder and inorganic salt into an immersing solution; extracting at a high pressure; and after carrying out probiotic fermentation and centrifuging, adding polydextrose and fructo-oligosaccharide syrup and sterilizing to obtain the composition of the probiotic fermented horseradish tree leaves. The composition can be used for preparing health products, foods and beverages capable of lowering blood fat and improving a sleeping function. An experiment shows that the composition of the probiotic fermented horseradish tree leaves can be used for reducing the contents of total cholesterol (TC) and triglyceride (TG) in blood serum, and improving the content of high density lipoprotein cholesterol (HDL-C) in the blood serum; the composition of the probiotic fermented horseradish tree leaves, disclosed by the invention, has a function of lowering a blood fat level.

Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and / or nicotinic acid metabolites in combination with leucine and / or a leucine metabolite, with or without resveratrol.

Disclosed herein are methods, compounds and compositions for preventing or treating a pancreatic disorder, including diabetes mellitus (e.g. type 1 and / or type 2 diabetes). The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for improving or at least stabilizing pancreatic function(s) and for the prevention and / or treatment of metabolic syndrome and its components. The invention further relates to methods, compounds and compositions for the prevention and / or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in patients in need thereof, including diabetic patients.

A pharmaceutical composition is an organic salt formed by an organic acid rosuvastatin and an organic base azelnidipine with a molar ratio of 1:1. The pharmaceutical composition can be made into any dosage forms together with a pharmaceutically-acceptable carrier for reducing blood pressure and blood lipid, reducing myocardial infarction and treating cerebral apoplexy. The inventive pharmaceutical composition has the advantages of stable physiochemical indexes, controllable product quality, and convenient administration.

The present invention relates to a preparation method of a high-quality fermented camel milk with function of auxiliarily lowering blood sugar. The method uses a combination of Lactobacillus plantarum Gr x 16 and other strains as leavening agents to prepare a fermented camel milk with function of auxiliarily lowering blood sugar. Especially the Lactobacillus plantarum Gr x 16, Lactobacillus casei gr x 12, Lactobacillus delbrueckii subsp. bulgaricus gr x 33 and Lactobacillus fermentum gr x 07 are mixed at a ratio of 1 : 1 : 1: 1 (v / v) into leavening agents. The fermentation prepared fermented camel milk is not only good in taste, is relative weak in post-acidification, at the same time has a blood sugar lowering effect on diabetic rats, and also can improve blood lipid levels and increase antioxidant capacity of diabetic rats.

A water-like fluid containing safe water and a significant quantity of soluble dietary fiber. The resulting solution is generally optically clear and has physical properties similar to potable water. The fluid is intended as a replacement for bottled, or other water, as a means to ensure proper hydration. Depending on the soluble fiber used the fluid is either non-caloric or extremely low in calories. The amount of soluble fiber is adjusted to a specific amount of water so that consumption of an adequate amount of fluid ensures hydration (e.g., eight 8 oz. glasses per day) will also providing an optimal amount of dietary fiber. This is particularly valuable in stressed situations where the diet may not provide adequate fiber without supplementation. The constant metered supply of fiber provided throughout the day is preferable to, and more convenient than, “bolus” administration of fiber through laxatives, etc. Additionally, the constant presence of soluble fiber in the digestive tract provides the known beneficial effects of moderating the postprandial increase in blood glucose, modulating serum lipid levels, and suppressing appetite.

The invention discloses a lotus leaf-based preparation for treating phlegm and blood stasis simultaneously. The pharmaceutical composition is prepared from the following traditional Chinese medicine extracts in parts by weight: 40-80 parts of lotus leaf extract, 10-20 parts of salvia miltiorrhiza extract, 30-60 parts of hawthorn extract, 10-20 parts of malaytea scurfpea fruit extract or salt scurfpea fruit extract, and 1-3 parts of senna extract. The invention further discloses application of the lotus leaf-based preparation in the preparation of medicines for treating phlegm turbidity and blood stasis simultaneously. The lotus leaf-based preparation disclosed by the invention has the activity in lowering blood lipid levels, and can be used for treating phlegm and blood stasis simultaneously and lowering the blood lipid levels.

The invention provides application of neohesperidin in preparing of diabetes preventive treatment compound medicines or health care products. Neohesperidin is extracted and separated from citrus grape fruit tengyuch euonymus bark layers and is subjected to glucose and lipid metabolism biological activity research, and just as naringin, neohesperidin can obviously increase hepatic cell glucose consumption, improve phosphorylation levels of glucose and lipid metabolism related protein adenosine monophosphate activated protein kinase (AMPK) and lipid synthesized key protein activated calcium carbonate (ACC) and cooperate to reduce triglyceride level in lipopexia hepatic cells molded by free fatty acid, has effects of prompting reduction of blood sugar and blood lipid levels, and effect concentration of neohesperidin is far lower than that of positive medicine metformin. Neohesperidin can serve as ancillary drugs or health care products to be used for preventive treatment of diseases related to glucose and lipid metabolism disorder.

Disclosed herein are methods, compounds and compositions for preventing or treating a renal disorder or chronic kidney diseases, including nephropathies such as diabetic nephropathy. The invention generally includes administering to a subject 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, e.g., 1,3-propanedisulfonic acid sodium salt. The invention also relates to methods, compounds and compositions for the prevention and / or treatment of for preventing or treating a renal disorder complication. The invention further relates to methods, compounds and compositions for the prevention and / or treatment of dyslipidemia, and more particularly for reducing levels of harmful serum lipid levels, especially cholesterol and triglycerides in diabetic patients.

The invention discloses a citrus chachiensis hortorum polymethoxylated flavonoids effective part and application thereof for treating hyperlipidaemia. The effective part is prepared from the following steps: step S1, extracting: grinding the citrus chachiensis hortorum, extracting by use of an alcohol-water solution, concentrating; step S2, removing impurities; sampling the concentrated solution obtained in the step S1 on macroporous resin, eluting and removing impurities by use of an ethanol water solution with the volume percent concentration of 40-45%, wherein the model of the macroporous resin is D101 type; and step S3, eluting: eluting the macroporous resin by use of the ethanol water solution with the volume percent concentration of 90% or more, collecting eluent, concentrating to obtain the citrus chachiensis hortorum polymethoxylated flavonoids effective part. The citrus chachiensis hortorum polymethoxylated flavonoids effective part provided by the invention can effectively lower the blood lipid level of hyperlipidaemia model mice, and is non-toxic, safe and effective, and can be used for preventing or treating hyperlipidaemia.

The invention relates to application of diosmetin in preparation of a medicine used for treating type 2 diabetes mellitus. Researches show that diosmetin can obviously improve glycometabolism of the type 2 diabetes mellitus, can improve insulin level and lower blood lipid level, can be used for preparing a blood-glucose-lowering medicine and provides a new medicine for treatment of the type 2 diabetes mellitus, thereby having significance on the treatment of diabetes mellitus.

Quinoline and quinoxaline compounds of formula I and III, wherein the substituents are as defined in claims 1 and 15, pharmaceutical compositions comprising these compounds and these compounds are effective in raising certain plasma lipid levels, including high-density lipoprotein cholesterol As well as the application of lowering certain other blood lipid levels such as LDL-cholesterol and triglycerides, thus for the treatment of diseases caused by abnormalities of low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides in mammals, including humans, such as Atherosclerosis and cardiovascular disease.

The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.

A water-like fluid containing safe water and a significant quantity of soluble dietary fiber. The resulting solution is generally optically clear and has physical properties similar to potable water. The fluid is intended as a replacement for bottled, or other water, as a means to ensure proper hydration. Depending on the soluble fiber used the fluid is either non-caloric or extremely low in calories. The amount of soluble fiber is adjusted to a specific amount of water so that consumption of an adequate amount of fluid ensures hydration (e.g., eight 8 oz. glasses per day) will also providing an optimal amount of dietary fiber. This is particularly valuable in stressed situations where the diet may not provide adequate fiber without supplementation. The constant metered supply of fiber provided throughout the day is preferable to, and more convenient than, 'bolus' administration of fiber through laxatives, etc. Additionally, the constant presence of soluble fiber in the digestive tract provides the known beneficial effects of moderating the postprandial increase in blood glucose, modulating serum lipid levels, and suppressing appetite.

The present invention relates to methods and materials used to express an HBM-like polypeptide derived from HBM, LRP5 or LRP6 in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the HBM-like polypeptides. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development and lipid modulation. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.

The invention discloses applications of firmicute probiotics in preventing and / or treating diabetes and relevant diseases, specifically, the firmicute probiotics are used or preparing a composition or a preparation. The composition or the preparation has the following one or more applications: (1) preventing and / or treating diabetes; (b) preventing and / or treating cardiovascular diseases; and / or (c) preventing and / or treating obesity. The firmicute probiotics can obviously inhibit the weight increase, reduce the serum glucose level, reduce the blood lipid level, improve the insulin resistance and / or reduce the glycosylated hemoglobin level, and thus the symptoms of diabetes and relevant diseases can be effectively alleviated.

The invention relates to a hypolipidemic drug combination formed by combining polyunsaturated fatty acid with plant polyphenol, in particular to hypolipidemic drug using EPA and EGCG or resveratrol as main active ingredients. Experimental studies show that the combination can remarkably lower blood lipid level and improve hemorheology and has remarkable effect on regulating blood lipid and preventing and treating diseases related to blood lipid metabolism abnormality. The combination is extensive in raw material source, low in cost and worthy of popularization and application.

The invention provides a method for extracting saffron petal total polysaccharide, belonging to the technical field of saffron active ingredient extraction. The method comprises the following steps: the saffron petal is extracted with ethanol and air-dried and the filter residue is mixed with water at a ratio of 1 g to (15 to 25) ml and then extracted at 95-105 DEG C for 3 hours, and then alcoholprecipitation is carried out to obtain a saffron petal total polysaccharide crude product; the saffron petal total polysaccharide crude product is redissolved and subjected to chromatographic purification by chromatography column so as to obtain the saffron petal total polysaccharide. The method disclosed by the invention has high saffron petal total polysaccharide yield, high activity, high DPPHfree radical and .OH scavenging ability. The acute toxicity evaluation is practically non-toxic, which can reduce the contents of TC and TG in the liver to certain extent. The saffron petal polysaccharide is indicated to have the functions of lowering blood lipid levels, effectively preventing high blood lipid levels, and effectively preventing hyperlipidemia caused by long-term high-fat diet.

The present invention relates to a new pharmaceutical composition containing nicotinic acid and / or nicotinamide and / or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and / or large intestine.

Methods for administering pressure changes to a user for the treatment and prevention of diseases and conditions are disclosed herein. Methods of administering Cyclic Variations in Altitude Conditioning Sessions (CVAC Session(s)) for the treatment of steroidogenesis, steroid levels, and treatment of serum lipid levels are disclosed herein. Also disclosed herein are methods of administering CVAC Session(s) for the treatment of steroid levels and steroidogenesis associated with HIV infection.

The invention provides a blood lipid level and coronary heart disease related rs7901016 detecting system and related application, particularly determines relevance between single nucleotide polymorphism rs7901016 and blood lipid level, provides application of reagent materials and / or instruments for detecting polymorphism of a rs7901016 locus in a sample of a to-be-tested individual to preparationof a detecting system for assessment of blood lipid level, dyslipidemia and / or coronary heart disease risks, and further provides the detecting system for assessment of the blood lipid level, dyslipidemia and / or coronary heart disease risks. The detecting system comprises the reagent materials and / or instruments for detecting polymorphism of the rs7901016 locus in the sample of the to-be-tested individual, wherein rs7901016 is remarkably related to LDL-C level, and rs7901016 locus T allele carriers are higher in LDL-C level and / or coronary heart disease risks than non-carriers.

A method of orally administering jojoba for fat reduction, blood lipid reduction, and cancer prevention and treatment in humans is disclosed. The method incorporates a sufficient quantity of jojoba, defatted jojoba meal, jojoba extract, defatted jojoba meal extract, naturally derived or synthesized simmondsin, or any naturally derived or synthesized simmondsin derivative or analogue, including aglycon, or any mixture thereof into an individual's diet in the form of a food, dietary supplement, or drug to provide simmondsin component in an amount greater than 0.01% of one's total daily diet by weight, or 0.05 gram / day. The dosage amount and duration of the administration can vary to achieve and maintain one's desired body composition and blood lipid levels. The dosage and duration of administration are increased for cancer prevention and treatment.

A use of a Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels is disclosed. Lactobacillus reuteri GMNL-263 (accession No.: CCTCC M 209263) specifically inhibits gene expression related to pro-inflammatory factor and lipid synthesis and promotes gene expression related to cholesterol metabolism. Lactobacillus reuteri GMNL-263 is utilized to produce a composition for decreasing blood lipid levels, thereby achieving the aim of hyperlipidemia treatment.

The invention provides a blood lipid level related single nucleotide polymorphism rs4883263 detecting system and related application, particularly determines relevance between single nucleotide polymorphism rs4883263 and blood lipid level, provides application of reagent materials and / or instruments for detecting polymorphism of a rs4883263 locus in a sample of a to-be-tested individual to preparation of a detecting system for assessment of blood lipid level and / or dyslipidemia risks, and further provides the detecting system for assessment of the blood lipid level and / or the dyslipidemia risks. The detecting system comprises the reagent materials and / or instruments for detecting polymorphism of the rs4883263 locus in the sample of the to-be-tested individual, wherein rs4883263 is remarkably related to HDL-C level, and rs4883263 locus C allele carriers are lower in HDL-C level and higher in dyslipidemia risks than non-carriers.

The invention relates to the technical field of biology and relates to treatment of type 2 diabetes mellitus with gene modified MSCs. The invention provides a recombinant stem cell which can overexpress an Exendin-4 protein. Medicines for treating obesity, fatty liver and type 2 diabetes mellitus can be prepared by utilizing the recombinant stem cell. The recombinant stem cell can be used for remarkably reducing the level of blood glucose and blood lipids and promoting the sensitivity of insulin. The treatment effect can be maintained for one month or more after a course of treatment, and therecombinant stem call can be used for treating metabolic diseases including obesity, fatty liver and type 2 diabetes mellitus, is safe and effective and has a long acting time.